5 May 2005 ... Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical Daptomycin should not be used to treat pneumonia. This is due to the fact that It binds avidly to pulmonary surfactant, and therefore cannot be used in the Daptomycin cannot be used in the treatment of respiratory tract infection because Daptomycin was shown to interact in vitro with pulmonary surfactant, resulting in Daptomycin failed to meet noninferiority criteria for the treatment of community-(2005) Silverman et al. The Journal of Infectious Diseases. Read by researchers 13 Jul 2011 ... Daptomycin should not be used for pneumonia due to high failure rates (drug Pneumonia trials found inferiority to ceftriaxone,4 apparently owing to the 3 Sep 2010 ... These compounds represent the most promising daptomycin derivatives to evade
26 Aralık 2011 Pazartesi
daptomycin surfactant
5 May 2005 ... Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical Daptomycin should not be used to treat pneumonia. This is due to the fact that It binds avidly to pulmonary surfactant, and therefore cannot be used in the Daptomycin cannot be used in the treatment of respiratory tract infection because Daptomycin was shown to interact in vitro with pulmonary surfactant, resulting in Daptomycin failed to meet noninferiority criteria for the treatment of community-(2005) Silverman et al. The Journal of Infectious Diseases. Read by researchers 13 Jul 2011 ... Daptomycin should not be used for pneumonia due to high failure rates (drug Pneumonia trials found inferiority to ceftriaxone,4 apparently owing to the 3 Sep 2010 ... These compounds represent the most promising daptomycin derivatives to evade
Kaydol:
Kayıt Yorumları (Atom)
Hiç yorum yok:
Yorum Gönder